Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMGO Imago BioSciences	$36.01	$35.96	$11.56 ▼ $36.09	$1.22B	2.82	171,367 shs	N/A
PBH Prestige Consumer Healthcare	$85.78 +1.5%	$83.59	$63.02 ▼ $90.04	$4.23B	0.44	298,535 shs	330,734 shs
PTCT PTC Therapeutics	$48.82 -0.1%	$46.48	$28.72 ▼ $58.38	$3.87B	0.52	861,055 shs	790,857 shs
RYTM Rhythm Pharmaceuticals	$61.36 -0.8%	$59.55	$36.27 ▼ $68.58	$3.90B	2.36	555,870 shs	484,159 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMGO Imago BioSciences	0.00%	0.00%	0.00%	0.00%	0.00%
PBH Prestige Consumer Healthcare	0.00%	-0.23%	+3.98%	+1.38%	+36.98%
PTCT PTC Therapeutics	0.00%	+6.29%	-1.41%	-11.65%	+39.37%
RYTM Rhythm Pharmaceuticals	0.00%	-1.60%	-3.82%	+11.75%	+73.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMGO Imago BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	3.601 of 5 stars	1.3	2.0	1.7	3.5	3.0	2.5	1.9
PTCT PTC Therapeutics	3.9634 of 5 stars	4.3	1.0	0.0	4.4	2.9	0.8	0.0
RYTM Rhythm Pharmaceuticals	3.9023 of 5 stars	3.5	1.0	0.0	4.3	3.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMGO Imago BioSciences	0.00	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	2.50	Moderate Buy	$93.33	8.81% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$63.75	30.58% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	24.86% Upside

Current Analyst Ratings Breakdown

Latest IMGO, PBH, RYTM, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PBH Prestige Consumer Healthcare	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00
5/7/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $67.00
5/7/2025	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$50.00 ➝ $40.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMGO Imago BioSciences	N/A	N/A	N/A	N/A	$6.40 per share	N/A
PBH Prestige Consumer Healthcare	$1.14B	3.73	$5.04 per share	17.03	$36.10 per share	2.38
PTCT PTC Therapeutics	$1.77B	2.18	$2.35 per share	20.80	($10.85) per share	-4.50
RYTM Rhythm Pharmaceuticals	$136.86M	28.52	N/A	N/A	$2.87 per share	21.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMGO Imago BioSciences	-$42.31M	-$1.84	N/A	N/A	N/A	N/A	-31.85%	-30.07%	N/A
PBH Prestige Consumer Healthcare	$209.34M	$4.29	20.09	18.02	2.69	19.13%	12.36%	6.39%	8/7/2025 (Estimated)
PTCT PTC Therapeutics	-$626.60M	$6.51	N/A	N/A	N/A	-50.32%	N/A	-16.44%	8/14/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	8/5/2025 (Estimated)

Latest IMGO, PBH, RYTM, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	PBH Prestige Consumer Healthcare	$1.30	$1.32	+$0.02	$1.00	$289.36 million	$296.52 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMGO Imago BioSciences	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	2.21%	N/A	44.29%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMGO Imago BioSciences	N/A	13.15	13.16
PBH Prestige Consumer Healthcare	0.56	3.68	2.20
PTCT PTC Therapeutics	N/A	2.10	2.04
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMGO Imago BioSciences	91.53%
PBH Prestige Consumer Healthcare	99.95%
PTCT PTC Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IMGO Imago BioSciences	14.90%
PBH Prestige Consumer Healthcare	1.60%
PTCT PTC Therapeutics	5.50%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMGO Imago BioSciences	27	33.82 million	28.78 million	Not Optionable
PBH Prestige Consumer Healthcare	540	49.42 million	48.75 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	72.88 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	58.02 million	Optionable

IMGO, PBH, RYTM, and PTCT Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Holdings Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 31 at 4:11 AM | marketbeat.com

Stifel Nicolaus Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $94.00

May 30 at 1:54 PM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.7% - Here's Why

May 30 at 1:39 PM | marketbeat.com

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism

May 30 at 11:54 AM | msn.com

3RYTM : 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

May 29 at 4:23 PM | benzinga.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 4.1% - Should You Sell?

May 29 at 4:16 PM | marketbeat.com

Funds Go All In On Weight-Loss Leader; Stock Nears Highs

May 29 at 1:20 PM | investors.com

Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 29 at 3:08 AM | marketbeat.com

Voloridge Investment Management LLC Purchases 27,214 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 25, 2025 | marketbeat.com

ProShare Advisors LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 25, 2025 | marketbeat.com

Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 24, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Trimmed by Frazier Life Sciences Management L.P.

May 23, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Buy" by Analysts

May 23, 2025 | americanbankingnews.com

Rafferty Asset Management LLC Sells 14,182 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 22, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Buys 43,904 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 22, 2025 | marketbeat.com

OMERS ADMINISTRATION Corp Takes $425,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 21, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Buy" from Analysts

May 20, 2025 | marketbeat.com

Lazard Asset Management LLC Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 18, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 621,432 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 16, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases 70,824 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 16, 2025 | marketbeat.com

Orbimed Advisors LLC Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMGO, PBH, RYTM, and PTCT Company Descriptions

Imago BioSciences NASDAQ:IMGO

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Prestige Consumer Healthcare NYSE:PBH

$85.78 +1.30 (+1.54%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$85.70 -0.08 (-0.09%)

As of 05/30/2025 04:37 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PTC Therapeutics NASDAQ:PTCT

$48.82 -0.07 (-0.14%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$48.25 -0.57 (-1.17%)

As of 05/30/2025 07:31 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.36 -0.52 (-0.84%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$60.82 -0.53 (-0.87%)

As of 05/30/2025 05:55 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time